Ketamine for the Treatment of Opioid Use Disorder and Depression
Brief Summary
The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine treatment. Study medications will be delivered twice per week for four weeks. If you are eligible and you decide to enroll in the study, your participation will last approximately 8 weeks, or 2 months.
Condition or Disease
- Depression
- Opioid-use Disorder
- Opioid Abuse
Phase
Study Design
| Study type: | Interventional |
|---|---|
| Status: | Not yet recruiting |
| Study results: | No Results Available |
| Age: | 18 Years to 65 Years (Adult, Older Adult) |
| Enrollment: | 30 () |
| Funded by: | Other|NIH |
Masking |
|
Clinical Trial Dates
| Start date: | Aug 30, 2020 | |
|---|---|---|
| Primary Completion: | Dec 01, 2021 | |
| Completion Date: | Dec 01, 2021 | |
| Study First Posted: | Nov 26, 2019 | |
| Results First Posted: | Aug 31, 2020 | |
| Last Updated: | Aug 10, 2020 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
Location
Eligibility Criteria
| Sex: | All |
|---|---|
| Minimum Age: | 18 |
| Maximum Age: | 65 |
More Details
| NCT Number: | NCT04177706 |
|---|---|
| Other IDs: | 00091292|K12DA031794 |
| Study URL: | https://ClinicalTrials.gov/show/NCT04177706 |
Last updated: Jun 17, 2022